Attention-deficit/hyperactivity disorder

Julie B Schweitzer, Catherine Fassbender, Lisa Lit, Gloria M. Reeves, Shanta Pearl Henderson Powell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent childhood psychiatric disorders. Most children with the disorder continue to exhibit significant symptoms as adults as well. Symptoms include inattention, hyperactivity or restlessness, and poor impulse control. ADHD is associated with a strong genetic component via twin, adoption, and family pedigree studies. Molecular genetic study findings, however, suggest genetic heterogeneity underlying similar ADHD phenotypes with support for many genes with only small effects typically contributing to the disorder. Both the dopaminergic and noradrenergic system appear to be altered in ADHD. Structural and functional alterations in frontal and cingulate cortices, basal ganglia, and cerebellar regions are routinely found in ADHD. These altered neurotransmitter systems and neuroanatomical regions subserve cognitive control and reward responsivity functioning - processes that are impaired in ADHD. Current recommendations for evaluating ADHD include the use of interviews and cross-informant and normed rating scales for children and adults with suspected ADHD. Possible comorbid disorders or disorders that may mimic ADHD should also be evaluated. The efficacy of pharmacological treatment for children and adults is well established. Stimulant medications are the recommended first-line psychopharmacological treatment of ADHD; however there are nonstimulant medications that are efficacious in treating ADHD and associated symptoms. School and parent-based behavioral interventions for ADHD can also address ADHD-associated symptoms in children. The benefits of medication or behavioral interventions may not be sustained after active treatment and monitoring of the treatment cease. There is initial support for the application of cognitive-behavioral treatment of ADHD symptoms in adults. Future research should attempt more targeted treatment informed by advances in neuroscience findings.

Original languageEnglish (US)
Pages (from-to)391-405
Number of pages15
JournalHandbook of Clinical Neurology
Volume106
DOIs
StatePublished - 2012

Fingerprint

Attention Deficit Disorder with Hyperactivity
Therapeutics
Psychomotor Agitation
Genetic Heterogeneity
Gyrus Cinguli
Frontal Lobe
Pedigree
Neurosciences
Basal Ganglia
Reward
Neurotransmitter Agents
Psychiatry
Molecular Biology

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Attention-deficit/hyperactivity disorder. / Schweitzer, Julie B; Fassbender, Catherine; Lit, Lisa; Reeves, Gloria M.; Powell, Shanta Pearl Henderson.

In: Handbook of Clinical Neurology, Vol. 106, 2012, p. 391-405.

Research output: Contribution to journalArticle

Schweitzer, Julie B ; Fassbender, Catherine ; Lit, Lisa ; Reeves, Gloria M. ; Powell, Shanta Pearl Henderson. / Attention-deficit/hyperactivity disorder. In: Handbook of Clinical Neurology. 2012 ; Vol. 106. pp. 391-405.
@article{e802982a9a06478a9460bfede3c0ed27,
title = "Attention-deficit/hyperactivity disorder",
abstract = "Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent childhood psychiatric disorders. Most children with the disorder continue to exhibit significant symptoms as adults as well. Symptoms include inattention, hyperactivity or restlessness, and poor impulse control. ADHD is associated with a strong genetic component via twin, adoption, and family pedigree studies. Molecular genetic study findings, however, suggest genetic heterogeneity underlying similar ADHD phenotypes with support for many genes with only small effects typically contributing to the disorder. Both the dopaminergic and noradrenergic system appear to be altered in ADHD. Structural and functional alterations in frontal and cingulate cortices, basal ganglia, and cerebellar regions are routinely found in ADHD. These altered neurotransmitter systems and neuroanatomical regions subserve cognitive control and reward responsivity functioning - processes that are impaired in ADHD. Current recommendations for evaluating ADHD include the use of interviews and cross-informant and normed rating scales for children and adults with suspected ADHD. Possible comorbid disorders or disorders that may mimic ADHD should also be evaluated. The efficacy of pharmacological treatment for children and adults is well established. Stimulant medications are the recommended first-line psychopharmacological treatment of ADHD; however there are nonstimulant medications that are efficacious in treating ADHD and associated symptoms. School and parent-based behavioral interventions for ADHD can also address ADHD-associated symptoms in children. The benefits of medication or behavioral interventions may not be sustained after active treatment and monitoring of the treatment cease. There is initial support for the application of cognitive-behavioral treatment of ADHD symptoms in adults. Future research should attempt more targeted treatment informed by advances in neuroscience findings.",
author = "Schweitzer, {Julie B} and Catherine Fassbender and Lisa Lit and Reeves, {Gloria M.} and Powell, {Shanta Pearl Henderson}",
year = "2012",
doi = "10.1016/B978-0-444-52002-9.00022-X",
language = "English (US)",
volume = "106",
pages = "391--405",
journal = "Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - Attention-deficit/hyperactivity disorder

AU - Schweitzer, Julie B

AU - Fassbender, Catherine

AU - Lit, Lisa

AU - Reeves, Gloria M.

AU - Powell, Shanta Pearl Henderson

PY - 2012

Y1 - 2012

N2 - Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent childhood psychiatric disorders. Most children with the disorder continue to exhibit significant symptoms as adults as well. Symptoms include inattention, hyperactivity or restlessness, and poor impulse control. ADHD is associated with a strong genetic component via twin, adoption, and family pedigree studies. Molecular genetic study findings, however, suggest genetic heterogeneity underlying similar ADHD phenotypes with support for many genes with only small effects typically contributing to the disorder. Both the dopaminergic and noradrenergic system appear to be altered in ADHD. Structural and functional alterations in frontal and cingulate cortices, basal ganglia, and cerebellar regions are routinely found in ADHD. These altered neurotransmitter systems and neuroanatomical regions subserve cognitive control and reward responsivity functioning - processes that are impaired in ADHD. Current recommendations for evaluating ADHD include the use of interviews and cross-informant and normed rating scales for children and adults with suspected ADHD. Possible comorbid disorders or disorders that may mimic ADHD should also be evaluated. The efficacy of pharmacological treatment for children and adults is well established. Stimulant medications are the recommended first-line psychopharmacological treatment of ADHD; however there are nonstimulant medications that are efficacious in treating ADHD and associated symptoms. School and parent-based behavioral interventions for ADHD can also address ADHD-associated symptoms in children. The benefits of medication or behavioral interventions may not be sustained after active treatment and monitoring of the treatment cease. There is initial support for the application of cognitive-behavioral treatment of ADHD symptoms in adults. Future research should attempt more targeted treatment informed by advances in neuroscience findings.

AB - Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent childhood psychiatric disorders. Most children with the disorder continue to exhibit significant symptoms as adults as well. Symptoms include inattention, hyperactivity or restlessness, and poor impulse control. ADHD is associated with a strong genetic component via twin, adoption, and family pedigree studies. Molecular genetic study findings, however, suggest genetic heterogeneity underlying similar ADHD phenotypes with support for many genes with only small effects typically contributing to the disorder. Both the dopaminergic and noradrenergic system appear to be altered in ADHD. Structural and functional alterations in frontal and cingulate cortices, basal ganglia, and cerebellar regions are routinely found in ADHD. These altered neurotransmitter systems and neuroanatomical regions subserve cognitive control and reward responsivity functioning - processes that are impaired in ADHD. Current recommendations for evaluating ADHD include the use of interviews and cross-informant and normed rating scales for children and adults with suspected ADHD. Possible comorbid disorders or disorders that may mimic ADHD should also be evaluated. The efficacy of pharmacological treatment for children and adults is well established. Stimulant medications are the recommended first-line psychopharmacological treatment of ADHD; however there are nonstimulant medications that are efficacious in treating ADHD and associated symptoms. School and parent-based behavioral interventions for ADHD can also address ADHD-associated symptoms in children. The benefits of medication or behavioral interventions may not be sustained after active treatment and monitoring of the treatment cease. There is initial support for the application of cognitive-behavioral treatment of ADHD symptoms in adults. Future research should attempt more targeted treatment informed by advances in neuroscience findings.

UR - http://www.scopus.com/inward/record.url?scp=84861157428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861157428&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-52002-9.00022-X

DO - 10.1016/B978-0-444-52002-9.00022-X

M3 - Article

C2 - 22608633

AN - SCOPUS:84861157428

VL - 106

SP - 391

EP - 405

JO - Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn

JF - Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn

SN - 0072-9752

ER -